Table 2.

Research status of HDACis.

Name of HDACis	Target	Status	Disease
Romidepsin	class I HDAC	animal model, cell experiment, phase 2A trial	AD [44]; atherosclerosis [45]; arthritis [46]; COVID-19 [47]; AIDS [48]
Apicidin	class I HDAC	animal model; cell experiment	AD [49]; PD [50]; cardiac diseases [51];
MS-275	class I HDAC	animal model	AD [5]; autism [52]; RA [38]; colitis [53]; diabetes [54]
RGFP966	HDAC3	animal model	HD [55]; AD [56,57]; atherosclerosis [58]; acute kidney injury [59]; inflammatory bowel disease [60]; allergic rhinitis [61]; hypothyroidism [62];
WK2-16	HDAC8	animal model	neurodegenerative diseases [63]; sepsis [64]; heart failure [65]
TMP269	Class IIa HDAC	cell experiment	stoke [66]; depression [67]; acute kidney injury [68]; autoimmune thyroid diseases [69]; rabies [70];
LMK235	HDAC4/5	animal model	PD [71]; heart disease [72]; sepsis [73]; trigeminal neuropathic pain [74]
T2943	HDAC5	animal model	Depression [75]
Tubacin	HDAC6	cell experiment,	PD [76]; hypertension [77]; Japanese encephalitis virus [78]
CKD-504	HDAC6	animal model	AD [13,79]; HD [79]
Resveratrol	SIRT1	phase I clinical trials; animal model;	PD (NCT03095092, NCT03093389, NCT03095105, NCT03091543, NCT03094156 and NCT03097211); AD [80]; systemic lupus; diabetic kidney disease [81]; erythematosus [82]; arthritis [83];
Honokiol	SIRT3	animal model	AD [17]; PD [84]; heart disease [85]
FT895	HDAC11	animal model	depression [86]; systemic lupus erythematosus [87]